# Immunoglobulins Delivered by AVV Vector for the Prevention of SIV Infection

> **NIH NIH R01** · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2021 · $731,021

## Abstract

Project Summary/Abstract
 In the classical approach to immunization against viral diseases, viral proteins are delivered or
expressed in the vaccine recipient and it is hoped that the resultant immune responses are protective. For a
variety of reasons, such a classic approach faces severe obstacles to success against HIV-1. The Desrosiers
laboratory has been investigating a nonclassical approach by which a viral vector, adeno-associated virus
(AAV), is used to achieve very long-term delivery of anti-HIV monoclonal antibodies (mAbs) with potent
neutralizing activity against a broad spectrum of HIV-1 isolates. AAV vectors have proven safe in human
testing and are currently the vector of choice for correction of hereditary enzyme/metabolism deficiencies.
When delivered intramuscularly, transgene expression can continue for years, decades, probably for life, as
long as the transgene product is not viewed as foreign. The vision is that a single inoculation of AAV vector
making a cocktail of potent broadly-neutralizing antibodies will provide sterilizing immunity for the rest of the
individual's life. Although an antibody may be viewed as a “self” protein, studies in monkeys have revealed that
a host antibody response may occur to the delivered mAb and this may severely limit the concentration of mAb
that can be achieved. The Desrosiers laboratory will continue its progress toward minimizing the anti-anti
problem and achieving consistent delivery of desirable antibodies using rhesus monkey models. These studies
are directly targeted to facilitating development of this concept for use in humans.

## Key facts

- **NIH application ID:** 10061523
- **Project number:** 5R01AI098446-09
- **Recipient organization:** UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- **Principal Investigator:** Ronald C Desrosiers
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $731,021
- **Award type:** 5
- **Project period:** 2012-07-18 → 2021-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10061523

## Citation

> US National Institutes of Health, RePORTER application 10061523, Immunoglobulins Delivered by AVV Vector for the Prevention of SIV Infection (5R01AI098446-09). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10061523. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*